Pituitary Homeobox 2 (PITX2) methylation predicts outcomes of adjuvant anthracycline chemotherapy in high-risk patients with lymph node-positive, estrogen receptor (ER) positive, and HER2-negative breast cancer (106, 107). Here, PITX2 is linked to breast cancer.